Furthermore, recent studies have shown that iMSC-mediated delivery of therapeutic agents, such as the ACVR2B-Fc fusion protein, can effectively alleviate HO symptoms in FOP model mice (Gao et al., 2024). The gene discussed is ACVR2B; the disease is fibrodysplasia ossificans progressiva.